hi fellow Fools,as promised, here my next post regarding ExelixisGDC-0973, Genetech/Roche's potent, selective MEK1/2 inhibitor, is used in combination with a PI3K inhibitor in the treatment of solid tumors.References:http://www.gene.com/gene/pipeline/status/oncology/mek/http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=ab...Interesting fact: GDC-0973 is also known as XL-518 (originally developped by Exelixis !). See reference here:http://www.medkoo.com/Anticancer-trials/GDC-0973.htmAt ESMO 2012 there will be a pivotal latebreaker presentation - LBA28 - of a phase-I trial; as this information is embargoed, the results will be available on Saturday, Sep 29, 2012, 9:15 am (Vienna time)the earliest.I intend to make the conclusion of this latebreaker available to you asap., since I plan to attend this sessionIt looks like Exelixis has another hot iron in the forge...take care, marsuculix(I am a molecular biologist and consultant to Swiss pharmaceutical companies - I will try to dig a hole to my former university colleagues working @ Roche - may be it pays off)
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar